Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2001

View Archived Issues

Genome-derived candidate for oncology identified as part of Millennium/Bayer alliance

Telik and the University of Arizona enter TRAP alliance

Human Genome Sciences licenses protein purification technology from Dyax

Update on Active Biotech's TTS products under clinical development

GlaxoSmithKline acquisition of Block Drug completed

Biogen expects product pipeline to double during 2001

Vion provides update of clinical programs

Results of phase III Metvix study show superiority to cryotherapy in treatment of AK

FDA approves Remeron SolTab for treatment of depression

Atrisone advances to phase III testing in acne

Continuous combined HRT with Climodien cleared for marketing in The Netherlands

Development of Merck compound for PD discontinued

Details on proposed merger of Medi-Ject and Permatec

Arakis and Bioglan Pharma to jointly develop novel psoriasis treatment

Pagoclone enters phase II for treatment of GAD

Arena receives second milestone payment from Lilly in CART collaboration

IntraBiotics completes patient enrollment in phase III Protegrin IB-367 Rinse study

Antex receives SBIR grant to develop microbead vaccine for traveler's diarrhea

Exclusive rights to NX-211 obtained by Gilead from GSK

First tablet preparation for bowel cleansing prior to colonoscopy now available in U.S.

Newly designed HIV-1 entry inhibitor holds great promise for clinical application

Monoclonal antibodies to alpha1 integrin designed at Biogen for inflammatory disorders

Adenosine uptake inhibitors useful for cerebral ischemia patented by Bayer

New oxazaheterocyle-based protease inhibitors reported by 3DP group

Antimicrobial series in development at Pharmacia

Anticancer compounds from Boehringer Ingelheim acting on kinases

Novel tryptase inhibitors with potential in therapy of influenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...